期刊
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
卷 647, 期 -, 页码 76-83出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.abb.2018.04.011
关键词
Poria cocos polysaccharide; Osteoclast; Bone resorption; MAPK; STAT3
资金
- Nature Science Foundation of China [81572164]
- National Key Technology Research and Development Program of China [2017YFC1103300]
- Guangxi Natural Science Foundation [2016GXNSFAA380295]
- University Scientific Research Project of Guangxi Province [KY2015YB054]
- Nanning Scientific Research and Technology Development Plan [20123142]
- Guangxi Scientific Research and Technology Development Plan Project [GKG13349003, 1598013-15]
- Western Australia Medical & Health Research Infrastructure Fund
- Arthritis Australia foundation
- University of Western Australia (UWA) Research Collaboration Awards
- Australian Health and Medical Research Council (NHMRC) [1107828, 1027932]
Pathological fractures caused by osteolytic lesions seriously threaten the health of patients. Osteoclasts play important roles in bone resorption whose hyperfunction are closely related to osteolytic lesions. Studies on osteoclast differentiation and function assist in the prevention of excessive bone loss associated diseases. We screened a variety of natural compounds with anti-inflammatory effect and found that poria cocos polysaccharide (PCP) inhibited RANKL-induced osteoclast formation and bone resorption via TRAcP staining, immunofluorescence, RT-PCR and western blot. PCP down-regulated phosphorylation of STAT3, P38, ERK and JNK, and thus repressed the expression of NFAcT1 and c-Fos during RANKL-induced osteoclastogenesis. Besides, the expression of bone resorption related genes such as TRAcP and CTSK was suppressed by PCP. The results suggest that PCP can be invoked as a candidate for the treatment of osteolytic diseases by inhibiting osteoclastogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据